Cargando…

Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin

BACKGROUND AND PURPOSE: The utilization of doxorubicin (DOX) in clinal trials is also challenging owing to its adverse effects, including low oral bioavailability, generation of reactive oxygen species (ROS), cardiotoxicity, and epithelial barrier damage. Recently, scavenging of ROS reduced the cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Minh-Dat Quoc, Trinh, Nhu-Thuy, Vu, Dung, Nguyen, Thu-Ha Thi, Dong, Hung Thanh, Vo, Toi Van, Vong, Long Binh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Association of Physical Chemists 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626516/
https://www.ncbi.nlm.nih.gov/pubmed/37937241
http://dx.doi.org/10.5599/admet.1845
_version_ 1785131353565560832
author Tang, Minh-Dat Quoc
Trinh, Nhu-Thuy
Vu, Dung
Nguyen, Thu-Ha Thi
Dong, Hung Thanh
Vo, Toi Van
Vong, Long Binh
author_facet Tang, Minh-Dat Quoc
Trinh, Nhu-Thuy
Vu, Dung
Nguyen, Thu-Ha Thi
Dong, Hung Thanh
Vo, Toi Van
Vong, Long Binh
author_sort Tang, Minh-Dat Quoc
collection PubMed
description BACKGROUND AND PURPOSE: The utilization of doxorubicin (DOX) in clinal trials is also challenging owing to its adverse effects, including low oral bioavailability, generation of reactive oxygen species (ROS), cardiotoxicity, and epithelial barrier damage. Recently, scavenging of ROS reduced the cytotoxicity of DOX, suggesting a new approach for using DOX as an anticancer treatment. Thus, in this study, non-silica and silica redox nanoparticles (denoted as RNP(N) and siRNP, respectively) with ROS scavenging features have been designed to encapsulate DOX and reduce its cytotoxicity. EXPERIMENTAL APPROACH: DOX-loaded RNP(N) (DOX@RNP(N)) and DOX-loaded siRNP (DOX@siRNP) were prepared by co-dissolving DOX with RNP(N) and siRNP, respectively. The size and stability of nanoparticles were characterized by the dynamic light scattering system. Additionally, encapsulation efficiency, loading capacity, and release profile of DOX@RNP(N) and DOX@siRNP were identified by measuring the absorbance of DOX. Finally, the cytotoxicity of DOX@RNP(N) and DOX@siRNP against normal murine fibroblast cells (L929), human hepatocellular carcinoma cells (HepG2), and human breast cancer cells (MCF-7) were also investigated. KEY RESULTS: The obtained result showed that RNP(N) exhibited a pH-sensitive character while silanol moieties improved the stability of siRNP in physiological conditions. DOX@RNP(N) and DOX@siRNP were formed at several tens of nanometers in diameter with narrow distribution. Moreover, DOX@siRNP stabilized under different pH buffers, especially gastric pH, and improved encapsulation of DOX owing to the addition of silanol groups. DOX@RNP(N) and DOX@siRNP maintained anticancer activity of DOX against HepG2, and MCF-7 cells, while their cytotoxicity on L929 cells was significantly reduced compared to free DOX treatment. CONCLUSION: DOX@RNP(N) and DOX@siRNP could effectively suppress the adverse effect of DOX, suggesting the potential to become promising nanomedicines for cancer treatments.
format Online
Article
Text
id pubmed-10626516
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher International Association of Physical Chemists
record_format MEDLINE/PubMed
spelling pubmed-106265162023-11-07 Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin Tang, Minh-Dat Quoc Trinh, Nhu-Thuy Vu, Dung Nguyen, Thu-Ha Thi Dong, Hung Thanh Vo, Toi Van Vong, Long Binh ADMET DMPK Original Scientific Paper BACKGROUND AND PURPOSE: The utilization of doxorubicin (DOX) in clinal trials is also challenging owing to its adverse effects, including low oral bioavailability, generation of reactive oxygen species (ROS), cardiotoxicity, and epithelial barrier damage. Recently, scavenging of ROS reduced the cytotoxicity of DOX, suggesting a new approach for using DOX as an anticancer treatment. Thus, in this study, non-silica and silica redox nanoparticles (denoted as RNP(N) and siRNP, respectively) with ROS scavenging features have been designed to encapsulate DOX and reduce its cytotoxicity. EXPERIMENTAL APPROACH: DOX-loaded RNP(N) (DOX@RNP(N)) and DOX-loaded siRNP (DOX@siRNP) were prepared by co-dissolving DOX with RNP(N) and siRNP, respectively. The size and stability of nanoparticles were characterized by the dynamic light scattering system. Additionally, encapsulation efficiency, loading capacity, and release profile of DOX@RNP(N) and DOX@siRNP were identified by measuring the absorbance of DOX. Finally, the cytotoxicity of DOX@RNP(N) and DOX@siRNP against normal murine fibroblast cells (L929), human hepatocellular carcinoma cells (HepG2), and human breast cancer cells (MCF-7) were also investigated. KEY RESULTS: The obtained result showed that RNP(N) exhibited a pH-sensitive character while silanol moieties improved the stability of siRNP in physiological conditions. DOX@RNP(N) and DOX@siRNP were formed at several tens of nanometers in diameter with narrow distribution. Moreover, DOX@siRNP stabilized under different pH buffers, especially gastric pH, and improved encapsulation of DOX owing to the addition of silanol groups. DOX@RNP(N) and DOX@siRNP maintained anticancer activity of DOX against HepG2, and MCF-7 cells, while their cytotoxicity on L929 cells was significantly reduced compared to free DOX treatment. CONCLUSION: DOX@RNP(N) and DOX@siRNP could effectively suppress the adverse effect of DOX, suggesting the potential to become promising nanomedicines for cancer treatments. International Association of Physical Chemists 2023-07-04 /pmc/articles/PMC10626516/ /pubmed/37937241 http://dx.doi.org/10.5599/admet.1845 Text en Copyright © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Original Scientific Paper
Tang, Minh-Dat Quoc
Trinh, Nhu-Thuy
Vu, Dung
Nguyen, Thu-Ha Thi
Dong, Hung Thanh
Vo, Toi Van
Vong, Long Binh
Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
title Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
title_full Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
title_fullStr Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
title_full_unstemmed Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
title_short Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
title_sort preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin
topic Original Scientific Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626516/
https://www.ncbi.nlm.nih.gov/pubmed/37937241
http://dx.doi.org/10.5599/admet.1845
work_keys_str_mv AT tangminhdatquoc preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin
AT trinhnhuthuy preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin
AT vudung preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin
AT nguyenthuhathi preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin
AT donghungthanh preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin
AT votoivan preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin
AT vonglongbinh preparationofselfassemblysilicaredoxnanoparticlestoimprovedrugencapsulationandsuppresstheadverseeffectofdoxorubicin